Mankind Pharma Share Price
Sector:
2312.00 +3.00 (0.13%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
2293.75
Today’s High
2331.45
52 Week Low
1910.10
52 Week High
3050.00
2303.50 -5.30 (-0.23%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
2293.20
Today’s High
2330.00
52 Week Low
1901.05
52 Week High
3054.80
Key Metrics
- Market Cap (In Cr) 95340.31
- Beta -
- Div. Yield (%) 0
- P/B 6.63
- TTM P/E 49.03
- Peg Ratio 4.21
- Sector P/E 22.67
- D/E 0.01
- Open Price 2326.6
- Prev Close 2309
Mankind Pharma Analysis
Price Analysis
-
1 Week-0.93%
-
3 Months-6.06%
-
6 Month-21.02%
-
YTD-20.03%
-
1 Year7.67%
Risk Meter
- 33% Low risk
- 33% Moderate risk
- 33% Balanced Risk
- 33% High risk
- 33% Extreme risk
Recos
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- 1 W Ago
- 1 M Ago
- 3 M Ago
- Strong Buy
- 5
- 5
- 5
- 5
- Buy
- 6
- 6
- 5
- 5
- Hold
- 3
- 3
- 3
- 2
- Sell
- 2
- 2
- 2
- 2
- Strong Sell
- 0.00
- 0.00
- 0.00
- 0.00
- Total
- 16
- 16
- 15
- 14
Mankind Pharma News
Why Mankind Pharma MD Rajeev Juneja wants to deepen gastro, derma presence
4 min read . 27 May 2025Stocks to watch: ITC, Indigo, IndusInd Bank, Honasa, RVNL among shares in focus
1 min read . 22 May 2025Q4 results today: ONGC, Indigo, Mankind Pharma, NALCO, Colgate, Oil India
1 min read . 21 May 2025Mankind Pharma Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2025
- Total Revenue
- 12207.44
- Selling/ General/ Admin Expenses Total
- 2692.37
- Depreciation/ Amortization
- 621.22
- Other Operating Expenses Total
- 3008.1
- Total Operating Expense
- 9810.73
- Operating Income
- 2396.71
- Net Income Before Taxes
- 2516.33
- Net Income
- 1990.96
- Diluted Normalized EPS
- 49.09
- Period
- 2025
- Total Assets
- 27759.53
- Total Liabilities
- 13427.14
- Total Equity
- 14332.39
- Tangible Book Valueper Share Common Eq
- -55.35
- Period
- 2025
- Cashfrom Operating Activities
- 2470.95
- Cashfrom Investing Activities
- -12682.95
- Cashfrom Financing Activities
- 10232.56
- Net Changein Cash
- 21.87
- Period
- 2024
- Total Revenue
- 10260.44
- Selling/ General/ Admin Expenses Total
- 2260.6
- Depreciation/ Amortization
- 378.42
- Other Operating Expenses Total
- 2287.69
- Total Operating Expense
- 8125.18
- Operating Income
- 2135.26
- Net Income Before Taxes
- 2397.94
- Net Income
- 1912.9
- Diluted Normalized EPS
- 47.66
- Period
- 2024
- Total Assets
- 11963.25
- Total Liabilities
- 2600.17
- Total Equity
- 9363.09
- Tangible Book Valueper Share Common Eq
- 191.72
- Period
- 2024
- Cashfrom Operating Activities
- 2152.45
- Cashfrom Investing Activities
- -2081.69
- Cashfrom Financing Activities
- 5.27
- Net Changein Cash
- 77.19
- Period
- 2023
- Total Revenue
- 8749.43
- Selling/ General/ Admin Expenses Total
- 3763.95
- Depreciation/ Amortization
- 325.86
- Total Operating Expense
- 7174.72
- Operating Income
- 1574.72
- Net Income Before Taxes
- 1671.24
- Net Income
- 1281.86
- Diluted Normalized EPS
- 32.06
- Period
- 2023
- Total Assets
- 9715.45
- Total Liabilities
- 2280.23
- Total Equity
- 7435.22
- Tangible Book Valueper Share Common Eq
- 141.21
- Period
- 2023
- Cashfrom Operating Activities
- 1813.3
- Cashfrom Investing Activities
- -1054.13
- Cashfrom Financing Activities
- -739.73
- Net Changein Cash
- 21.76
- Period
- 2022
- Total Revenue
- 7781.56
- Selling/ General/ Admin Expenses Total
- 3209.56
- Depreciation/ Amortization
- 166.56
- Total Operating Expense
- 5929.56
- Operating Income
- 1851.99
- Net Income Before Taxes
- 1974.6
- Net Income
- 1433.48
- Diluted Normalized EPS
- 35.36
- Period
- 2022
- Total Assets
- 9147.74
- Total Liabilities
- 2992.51
- Total Equity
- 6155.23
- Tangible Book Valueper Share Common Eq
- 106.36
- Period
- 2022
- Cashfrom Operating Activities
- 919.78
- Cashfrom Investing Activities
- -1369.14
- Cashfrom Financing Activities
- 604.62
- Net Changein Cash
- 155.73
- Period
- 2021
- Total Revenue
- 6214.43
- Selling/ General/ Admin Expenses Total
- 2583.6
- Depreciation/ Amortization
- 118.92
- Other Operating Expenses Total
- 50.58
- Total Operating Expense
- 4682.26
- Operating Income
- 1532.18
- Net Income Before Taxes
- 1691.61
- Net Income
- 1265.43
- Diluted Normalized EPS
- 31.98
- Period
- 2021
- Total Assets
- 6372.63
- Total Liabilities
- 1650.63
- Total Equity
- 4722
- Tangible Book Valueper Share Common Eq
- 116.9
- Period
- 2021
- Cashfrom Operating Activities
- 1137.24
- Cashfrom Investing Activities
- -1222.21
- Cashfrom Financing Activities
- -7.81
- Net Changein Cash
- -92.4
- Period
- 2020
- Total Revenue
- 5865.23
- Selling/ General/ Admin Expenses Total
- 2294.37
- Depreciation/ Amortization
- 99.05
- Other Operating Expenses Total
- 40.14
- Total Operating Expense
- 4518.47
- Operating Income
- 1346.77
- Net Income Before Taxes
- 1437.74
- Net Income
- 1030.43
- Diluted Normalized EPS
- 27.27
- Period
- 2020
- Total Assets
- 5073.29
- Total Liabilities
- 1587.98
- Total Equity
- 3485.31
- Tangible Book Valueper Share Common Eq
- 85.85
- Period
- 2020
- Cashfrom Operating Activities
- 1069.71
- Cashfrom Investing Activities
- -439.16
- Cashfrom Financing Activities
- -530.74
- Net Changein Cash
- 103.42
- Period
- 2025-03-31
- Total Revenue
- 3079.37
- Selling/ General/ Admin Expenses Total
- 715.8
- Depreciation/ Amortization
- 230.87
- Other Operating Expenses Total
- 805
- Total Operating Expense
- 2627.05
- Operating Income
- 452.32
- Net Income Before Taxes
- 515.43
- Net Income
- 420.77
- Diluted Normalized EPS
- 10.29
- Period
- 2025-03-31
- Total Assets
- 27759.53
- Total Liabilities
- 13427.14
- Total Equity
- 14332.39
- Tangible Book Valueper Share Common Eq
- -55.35
- Period
- 2025-03-31
- Cashfrom Operating Activities
- 2470.95
- Cashfrom Investing Activities
- -12682.95
- Cashfrom Financing Activities
- 10232.56
- Net Changein Cash
- 21.87
- Period
- 2024-12-31
- Total Revenue
- 3230
- Selling/ General/ Admin Expenses Total
- 709.71
- Depreciation/ Amortization
- 192.3
- Other Operating Expenses Total
- 755.27
- Total Operating Expense
- 2592.5
- Operating Income
- 637.5
- Net Income Before Taxes
- 497.33
- Net Income
- 380.23
- Diluted Normalized EPS
- 9.44
- Period
- 2024-12-31
- Period
- 2024-12-31
- Period
- 2024-09-30
- Total Revenue
- 3076.51
- Selling/ General/ Admin Expenses Total
- 646.43
- Depreciation/ Amortization
- 105.62
- Other Operating Expenses Total
- 705.15
- Total Operating Expense
- 2332.09
- Operating Income
- 744.42
- Net Income Before Taxes
- 849.32
- Net Income
- 653.47
- Diluted Normalized EPS
- 16.28
- Period
- 2024-09-30
- Total Assets
- 13982.25
- Total Liabilities
- 3417.49
- Total Equity
- 10564.76
- Tangible Book Valueper Share Common Eq
- 222.76
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 1139.33
- Cashfrom Investing Activities
- -1035.42
- Cashfrom Financing Activities
- 240.51
- Net Changein Cash
- 344.62
- Period
- 2024-06-30
- Total Revenue
- 2893.42
- Selling/ General/ Admin Expenses Total
- 633.78
- Depreciation/ Amortization
- 107.74
- Other Operating Expenses Total
- 765.35
- Total Operating Expense
- 2319.4
- Operating Income
- 574.02
- Net Income Before Taxes
- 667.62
- Net Income
- 536.49
- Diluted Normalized EPS
- 13.37
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 2422.24
- Selling/ General/ Admin Expenses Total
- 577.94
- Depreciation/ Amortization
- 99.78
- Other Operating Expenses Total
- 523.25
- Total Operating Expense
- 1935.72
- Operating Income
- 486.52
- Net Income Before Taxes
- 571.91
- Net Income
- 471.24
- Diluted Normalized EPS
- 11.75
- Period
- 2024-03-31
- Total Assets
- 11963.25
- Total Liabilities
- 2600.17
- Total Equity
- 9363.09
- Tangible Book Valueper Share Common Eq
- 191.72
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 2152.45
- Cashfrom Investing Activities
- -2081.69
- Cashfrom Financing Activities
- 5.27
- Net Changein Cash
- 77.19
- Period
- 2023-12-31
- Total Revenue
- 2606.96
- Selling/ General/ Admin Expenses Total
- 568.35
- Depreciation/ Amortization
- 109.73
- Other Operating Expenses Total
- 604.51
- Total Operating Expense
- 2110.18
- Operating Income
- 496.78
- Net Income Before Taxes
- 562.33
- Net Income
- 453.76
- Diluted Normalized EPS
- 11.31
- Period
- 2023-12-31
- Period
- 2023-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Mankind Pharma Technical
Moving Average
SMA
- 5 Day2305.7
- 10 Day2337.19
- 20 Day2362.44
- 50 Day2445.46
- 100 Day2407.09
- 300 Day2521.32
Mankind Pharma Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Hyundai Motor India
- 2125.4
- 0.2
- 0.01
- 2145
- 1542.95
- 172697.48
- Bajaj Housing Finance
- 122
- 0.35
- 0.29
- 188.45
- 103
- 101654.48
- Mankind Pharma
- 2312
- 3
- 0.13
- 3050
- 1910.1
- 95340.31
- Swiggy
- 405.05
- 4.85
- 1.21
- 617
- 297
- 101005.17
- Ntpc Green Energy
- 106.75
- -0.45
- -0.42
- 155.3
- 84.6
- 89741.78
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Hyundai Motor India
- 30.63
- 10.6
- -
- -
- Bajaj Housing Finance
- 44.31
- 5.08
- 13.08
- 21.32
- Mankind Pharma
- 47.03
- 6.65
- 21.54
- 17.7
- Swiggy
- -
- 9.76
- -
- -34.64
- Ntpc Green Energy
- 160.06
- 4.9
- -
- -
Mankind Pharma Shareholding
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 21-May-25
- Audited Results
- 23-Jan-25
- Quarterly Results
- 05-Nov-24
- Quarterly Results
- 31-Jul-24
- Quarterly Results
- 15-May-24
- Audited Results & Others
- 31-Jan-24
- Quarterly Results
- 31-Oct-23
- Quarterly Results
- 02-Aug-23
- Quarterly Results
- 30-May-23
- Audited Results
- Meeting Date
- Announced on
- Purpose
- 24-Dec-24
- 21-Nov-24
- POM
- 09-Aug-24
- 18-Jul-24
- AGM
- 22-Sept-23
- 02-Aug-23
- AGM



